Clinical Trials | November 26, 2025
Novo Nordisk’s new diabetes combo drug delivers big wins in mid-stage trial
The trial tested six injectable doses and three oral doses over as long as 36 weeks
The trial tested six injectable doses and three oral doses over as long as 36 weeks
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
Glucagon-Like Peptide-1 is a natural hormone that regulates blood sugar, controls appetite, and slows digestion
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
Enabling a new era in minimally invasive obesity treatment across Europe
Poviztra is a second brand of Wegovy
Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Encouraging early detection and breaking the silence around men’s health
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
Subscribe To Our Newsletter & Stay Updated
